N,N-二乙基-3-硼苯磺酰胺 | 871329-58-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N,N-二乙基-3-硼苯磺酰胺
• 中文别名: (3-(N,N-二乙基氨磺酰)苯基)硼酸；3-(二乙基磺酰氨基)苯硼酸
• 英文名称: 3-(diethylsulfamoyl)phenyl boronic acid
• 英文别名: 3-(N,N-diethylsulfamoyl)phenylboronic acid；N,N-Diethyl 3-boronobenzenesulfonamide；[3-(diethylsulfamoyl)phenyl]boronic acid
• CAS: 871329-58-7
• 化学式: C₁₀H₁₆BNO₄S
• 分子量: 257.118
• InChiKey: PSMCZVAPCNNYTE-UHFFFAOYSA-N

物化性质

• 熔点：
  120-123
• 沸点：
  450.3±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  N,N-二乙基-3-硼苯磺酰胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 18.0h， 生成 3-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-diethylbenzenesulfonamide
  参考文献：
  名称：

  3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors

  摘要：

  本发明涉及由式I描述的化合物： 其盐，它们的合成，以及它们作为ITK和JAK3抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或疾病的方法，这些疾病与异常细胞生长有关，如自身免疫、炎症、类风湿关节炎、系统性红斑狼疮、动脉粥样硬化、溃疡性结肠炎、银屑病性关节炎、银屑病、克罗恩病、代谢和癌症疾病。本发明还提供包括本发明化合物的药学上可接受的组合物以及使用这些组合物的方法和制备本发明化合物的方法。

  公开号：

  US20140315909A1

文献信息

• Design and Evaluation of Novel Biphenyl Sulfonamide Derivatives with Potent Histamine H₃ Receptor Inverse Agonist Activity
  作者：Jonathan A. Covel、Vincent J. Santora、Jeffrey M. Smith、Rena Hayashi、Charlemagne Gallardo、Michael I. Weinhouse、Jason B. Ibarra、Jeffrey A. Schultz、Douglas M. Park、Scott A. Estrada、Brian J. Hofilena、Michelle D. Pulley、Brian M. Smith、Albert Ren、Marissa Suarez、John Frazer、Jeffrey Edwards、Erin K. Hauser、Jodie Lorea、Graeme Semple、Andrew J. Grottick

  DOI：10.1021/jm900857n

  日期：2009.9.24

  Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were shown to be potent and selective antagonists of the H3 receptor. Several of these compounds demonstrated in vivo activity in a rat model of (R)-α-methyl histamine (RAMH) induced dipsogenia, and one compound (4e) provided an increase in wakefulness in rats as measured by polysomnographic methods. However, more detailed analysis of the PK/PD

  组胺-H 3受体的拮抗作用是探索增加清醒性以治疗诸如过度日间嗜睡（EDS）以及其他睡眠或认知障碍之类的疾病的一种策略。含有苯乙基-R -2-甲基吡咯烷的联苯磺酰胺化合物被证明是H 3受体的有效和选择性拮抗剂。这些化合物中的几种在（R）-α-甲基组胺（RAMH）诱导的成瘾症的大鼠模型中具有体内活性，一种化合物（4e）通过多导睡眠监测法测量了大鼠的清醒度。但是，对PK / PD关系的更详细分析表明存在共同的活性代谢物，这可能会使该系列化合物无法进一步开发。
• [EN] SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS<br/>[FR] DÉRIVÉS SUBSTITUÉS DE 1H-PYRROLO[2,3-B]PYRIDINE ET 1H-PYRAZOLO[3,4-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASES 2 INDUCTIBLES PAR UN SEL (SIK2)
  申请人：ARRIEN PHARMACEUTICALS LLC

  公开号：WO2014093383A1

  公开（公告）日：2014-06-19

  The present invention relates to compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.

  本发明涉及符合以下公式I、IA或IB的化合物：药学上可接受的组合物、其盐、它们的合成以及它们作为SIK2抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或紊乱的方法，如癌症、中风、心血管疾病、肥胖和2型糖尿病。
• Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K<i>α</i> inhibitors
  作者：Rui Chen、Zhongyuan Wang、Lijie Sima、Hu Cheng、Bilan Luo、Jianta Wang、Bing Guo、Shunyi Mao、Zhixu Zhou、Jingang Peng、Lei Tang、Xinfu Liu、Weike Liao

  DOI：10.1080/14756366.2022.2155638

  日期：2023.12.31

  PI3K pathway has become a desirable strategy for cancer treatment. In this work, a series of 2, 6, 8-substituted Imidazo[1,2-a]pyridine derivatives were designed and screened for their activities against PI3Kα and a panel of PI3Kα-addicted cancer cells. Among them, compound 35 was identified as a PI3Kα inhibitor with nanomolar potency as well as acceptable antiproliferative activity. Flow cytometry analysis

  摘要 抑制 PI3K 通路已成为癌症治疗的理想策略。在这项工作中，设计了一系列 2、6、8-取代的咪唑并 [1,2-a] 吡啶衍生物，并筛选了它们对 PI3K α和一组 PI3K α成瘾癌细胞的活性。其中，化合物35被鉴定为具有纳摩尔效力和可接受的抗增殖活性的 PI3K α抑制剂。流式细胞术分析证实35在 T47D 细胞中诱导细胞周期停滞和细胞凋亡。此外，它还显示出理想的体外ADME 特性。35的设计、合成和 SAR 探索在其中进行了描述。
• Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway
  作者：Daryl Staveness、Rana Abdelnabi、Katherine E. Near、Yu Nakagawa、Johan Neyts、Leen Delang、Pieter Leyssen、Paul A. Wender

  DOI：10.1021/acs.jnatprod.5b01017

  日期：2016.4.22

  Chikungunya virus (CHIKV) has been spreading rapidly, with over one million confirmed or suspected cases in the Americas since late 2013. Infection with CHIKV causes devastating arthritic and arthralgic symptoms. Currently, there is no therapy to treat this disease, and the only medications focus on relief of symptoms. Recently, protein kinase C (PKC) modulators have been reported to inhibit CHIKV-induced cell death in cell assays. The salicylate-derived bryostatin analogues described here are structurally simplified PKC modulators that are more synthetically accessible than the natural product bryostatin 1, a PKC modulator and clinical lead for the treatment of cancer, Alzheimer's disease, and HIV eradication. Evaluation of the anti-CHIKV activity of these salicylate-derived bryostatin analogues in cell culture indicates that they are among the most potent cell-protective agents reported to date. Given that they are more accessible and significantly more active than the parent natural product, they represent new therapeutic leads for controlling CHIKV infection. Significantly, these analogues also provide evidence for the involvement of a PKC-independent pathway. This. adds a fundamentally distinct aspect to the importance or involvement of PKC modulation in inhibition of chikungunya virus replication, a topic of recent and growing interest.